National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Upadacitinib (Rinvoq®) for ankylosing spondylitis. HTA ID: 21039

Upadacitinib (Rinvoq®) is indicated for active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 01/09/2021
Rapid review completed 11/10/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.